Role of neuropeptides in migraine: Where do they stand in the latest expert recommendations in migraine treatment?

Drug Development Research

Volumn 68, Issue 6, 2007, Pages 294-314

  Samsam, Mohtashem ^a,b,c,f   Covenas R ^c   Ahangari, R ^a,c   Yajeya, J ^c,d   Narvaez J A ^e  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b International University of Health Sciences (IUHS)   (Trinidad and Tobago)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e UNIVERSITY OF MÁLAGA   (Spain)

^f UNIVERSITY OF CENTRAL FLORIDA   (United States)

Author keywords

Calcitonin gene related peptide; Headache; Substance P; Trigeminovascular system

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE[8-37]; CHOLECYSTOKININ; CYCLIC GMP; ENDORPHIN; GALANIN; GASTRIN RELEASING PEPTIDE; GLYCERYL TRINITRATE; HISTAMINE; NEUROKININ A; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTENSIN; NITRIC OXIDE SYNTHASE; PEPTIDE HISTIDINE ISOLEUCINE; PROSTAGLANDIN; PROSTAGLANDIN E2; SEROTONIN; SODIUM CHANNEL; SOMATOSTATIN; SUBSTANCE P; SUMATRIPTAN; UNINDEXED DRUG; VASOACTIVE AGENT; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPRESSIN;

BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN MITOCHONDRION; CLUSTER HEADACHE; DRUG CHOICE; ENERGY METABOLISM; HEADACHE; HUMAN; MIGRAINE; NEUROCHEMISTRY; NONHUMAN; PATHOPHYSIOLOGY; PERIAQUEDUCTAL GRAY MATTER; PROPHYLAXIS; RECEPTOR BLOCKING; REVIEW; TRIGEMINAL NERVE; VASODILATATION;

EID: 38149102414     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20193     Document Type: Review

References (270)

1. Afridi SK, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RS, Goadsby PJ. 2005. A positron emission tomographic study in spontaneous migraine. Arch Neurol 62:1270-1275.
2. Ahn AH, Basbaum AI. 2006. Tissue injury regulates serotonin ID receptor expression: implications for the control of migraine and inflammatory pain. J Neurosci 26:8332-8338.
3. Akerman S, Goadsby PJ. 2005. Topiramate inhibits trigeminovascular activation: an intravital microscopy study. Br J Pharmacol 146:7-14.
4. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. 2002. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 137:62-68.
5. Alessandri M, Massanti L, Geppetti P, Bellucci G, Cipriani M, Fanciullacci M. 2006. Plasma changes of calcitonin gene-related peptide and substance P in patients with dialvsis headache. Cephalalgia 26:1287-1293.
6. Al-Rodhan NR, Richelson E, Gilbert JA, McCormick DJ, Kanba KS, Pfenning MA, Nelson A, Larson EW, Yaksh TL. 1991. Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem. Brain Res 557:227-235.
7. Alvarez FJ, Priestly JV 1990a. Anatomy of somatostatin-immunoreactive fibers and cell bodies in the rat trigeminal subnucleus caudalis. Neuroscience 38:343-357.
8. Alvarez FJ, Priestly JV. 1990b. Ultrastructure of somatostatin- immunoreactive nerve terminals in laminae I and II of the rat trigeminal subnucleus caudalis. Neuroscience 38:359-371.
9. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. 1982. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240-244.
10. Arommaa M, Rautava P, Sillanpaa M, Helenius H, Ojanlatva A. 1999. Familial occurrence of headache. Cephalalgia 25:49-52.
11. Arulmani U, Gupta S, Massen Van Den Brink A, Centurión D, Villalón CM, Saxena PR. 2006. Experimental migraine models and their relevance in migraine therapy. Cephalalgia 26:642-659.
12. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Caster R. 2005. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Cardiol 45:489-492.
13. Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. 2001. Brainstem activation specific to migraine headache. Lancet 357:1016-1017.
14. Bartsch T, Levy MJ, Knight YE, Goadsby PJ. 2005. Inhibition of nociceptive dural input in the trigeminal nucleus caudalis by somatostatin receptor blockade in the posterior hypothalamus. Pain 117:30-39.
15. Basbaum A, Field H. 1979. The origin of descending pathways in the dorsolateral funiculus of the spinal cord of the cat and rat: further studies on the anatomy of pain modulation. J Comp Neurol 187:513-532.
16. Basbaum A I, Woolf CJ. 1999. Pain. Curr Biol 9:R429-R431.
17. Basbaum A I, Jessell TM. 2000. The perception of pain. In: Kandel ER, Schwartz HJ, Jessell TM, editors. Principles of neural science, 4th ed. New York: McGraw-Hill. p 472-491.
18. Behbehani MM. 1992. Physiological mechanisms of the analgesic effect of neurotensin. Ann NY Acad Sci 668:253-265.
19. Behbehani M, Fields H. 1979. Evidence that an excitatory connection between the periaqueductal gray and nucleus raphe magnus mediates stimulation produced analgesia. Brain Res 170:85-93.
20. Behbehani M, Pert A. 1984. A mechanism for analgesic effect of neurotensin as revealed by behavioural and electro-physiological techniques. Brain Res 324:35-42.
21. Beitz AJ. 1982. The organization of afferent projections to midbrain periaqueductal region of the rat. Neuroscience 7:135-159.
22. Bellamy J, Bowen EJ, Russo AF, Durham PL. 2006. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci 23:2057-2066.
23. Benemei S, Nicoletti P, Capone JA, Geppetti P. 2007. Pain pharmacology in migraine: focus on CGRP and CGRP receptors. Neurol Sci 28(Suppl 2):S89-S93.
24. Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. 2006. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia 26:1304-1309.
25. Blomstrand F, Kharibi S, Muyrierman H, Hansson E, Olsson T, Ronnback L. 1999. 5-Hydroxytryptamine and glutamate modulate velocity and extent of intercellular calcium signalling in hippocampal astroglial cells in primary cultures. Neuroscience 88:1241-1253.
26. Boes CJ, Black DF, Dodick DW. 2006. Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol 26:232-241.
27. Boska M, Welch K, Barker P, Nelson J, Schultz L. 2002. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology 58:1227-1233.
28. Bon J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. 2001. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 21:804-812.
29. Bourgoin S, Le Bars D, Clot A M, Hamon M, Cesselin F. 1988. Spontaneous and evoked release of methionine-enkephalin-like material from the spinal cord of arthritic rats in vivo. Pain 32:107-114.
30. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. 1985. Calcitonin gene-related peptide is a potent vasodilator. Nature 313:54-56.
31. Brändli P, Löffler BM, Breu V, Osterwalder R, Maire JP, Clozel M. 1996. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater. Pain 64:315-322.
32. Brimijoin S, Lundberg JM, Brodin E, Hökfelt T, Nilsson G. 1980. Axonal transport of substance P in the vagus and sciatic nerves of the guinea pig. Brain Res 191:443-457.
33. Bruyn GW 1984. Intracranial arteriovenous malformation and migraine. Cephalalgia 4:191-207.
34. Buldyrev I, Tanner NM, Hsieh HY, Dodd EG, Nguyen LT, Balkowiec A. 2006. Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J Neurochem 99:1338-1350.
35. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. 2000. An association between migraine and cutaneous allodynia. Ann Neurol 47:614-624.
36. Buzzi MG, Carter WB, Shimizu T, Heath III H, Moskowitz MA. 1991. Dihydroergotamine and Sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacol 30:1193-1200.
37. Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schäffer M, Loeffler JP, Stein C. 1997. Immune cell derived â-endorphin: production, release and control of inflammatory pain in rats. J Clin Invest 100:142-148.
38. Cabot PJ, Carter L, Schäffer M, Stein C. 2001. Methionine- enkephalin- and Dynorphin A-release from immune cells and control of inflammatory pain. Pain 93:207-212.
39. Cesselin F, Le Bars D, Bourgoin S, Artaud F, Gozlan H, Clot A M, Besson J M, Hamon M. 1985. Spontaneous and evoked release of methionine-enkephalin-like material from the rat spinal cord in vivo. Brain Res 339:305-313.
40. Cipolla G, Sacco S, Crema F, Moro E, De Ponti F, Frigo G. 2001. Gastric motor effects of triptans: open questions and future perspectives. Pharmacol Res 43:205-210.
41. Clayton JS, Gaskin PJ, Beattie DT 1997. Attenuation of fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea pig. Brain Res 775:74-80.
42. Clineschmidt BV, McGuffin JC, Bunting PB. 1979. Neurotensin: antinociceptive action in rodents. Eur J Pharmacol 54:129-139.
43. Clineschmidt BV, Martin CiE, Veber DF 1982. Antinociceptive effects of neurotensin and neurotensin-related peptides. Ann NY Acad Sci 400:283-306.
44. Cohen AS, Goadsby PJ. 2006. Functional neuroimaging of primary headache disorders. Expert Rev Neurother 6:1159-1171.
45. Counis R, Laverrière JN, Garrel-Lazayres G, Cohen-Tannoudji J, Larivière S, Bleux C, Magre S. 2007. What is the role of PACAP in gonadotrope function? Peptides (in press).
46. Cutrer FM. 2001. Antiepileptic drugs: how they work in headache. Headache 41(Suppl 1)S3-S10.
47. Dalsgaard CJ, Vincent SR, Hökfelt T, Wiesenfeld-hallin Z, Gustafsson L, Elde R, Dockray GJ. 1984. Effects of cysteamine on pain behaviour and on somatostatin and substance P-like immunoreactivity in the substantia gelatinosa of the rat. Eur J Pharmacol 104:295-301.
48. De Vries P, Villalón CM, Saxena PR. 1999. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 375:61-74.
49. Del Fiacco M, Quarta M. 1994. Somatostatin, galanin and peptide histidine isoleucine in the newborn and adult human trigeminal ganglion and spinal nucleus: immunohistochemistry, neuronal morphometry and co-localization with substance P. J Chem Neuroanat 7:171-184.
50. Dichgans M, Freilinger T, Eckstein G, Babini E, Lorenz-Depiereux B, Biskup S, Ferrari MD, Herzog J, van den Maagdenberg AM, Pusch M, Strom TM. 2005. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366:371-377.
51. Diener HC. 1996. Substance-P antagonist RPR100893-201 is not effective in human migraine attacks. In: Olesen J, Tfelt-Hansen P, editors. Proceedings of the Sixth International Headache Seminar. New York: Lippincott-Raven.
52. Dolly JO, Aoki KR. 2006. The structure and mode of action of different botulinum toxins. Eur J Neurol 13(Suppl 4):1-9.
53. Donaldson C, Boers PM, Hoskin KL, Zagami AS, Lambert GA. 2002. The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology 42:374-385.
54. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W. 2000. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 129:420-423.
55. Durham PL, Niemann C, Cady R. 2006. Repression of stimulated calcitonin gene-related peptide secretion by topiramate. Headache 46:1291-1295
56. Edvinsson L. 2001. Sensory nerves in man and their role in primary headaches. Cephalalgia 21:761-764.
57. Edvinsson L. 2006. Neuronal signal substances as biomarkers of migraine. Headache 46:1088-1094.
58. Edvinsson L, Uddman R. 2005. Neurobiology of primary headaches. Brain Res Rev 48:438-456.
59. Edvinsson L, Brodin E, Jansen I, Uddman R. 1988. Neurokinin A in cerebral vessels: characterization, localization and effects in vitro. Regul Pept 20:181-197.
60. Edvinsson L, Alm R, Shaw D, Rutledge RZ, Koblan KS, Longmore J, Kane SA. 2002. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 434:49-53.
61. Erspamer V. 1981. The tachykinin peptide family. Trends Neurosci 4:267-269.
62. Esch F, Bohlen P, Ling N, Benoit R, Brazeau P, Guillemin R. 1980. Primary structure of ovine hypothalamic somatostatin-28 and somatostatin-25. Proc Natl Acad Sci USA 77:6827-6831.
63. Escott KJ, Beattie DT, Connor HE, Brain SD. 1995. Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide. Brain Res 669:93-99.
64. Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. 2006. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 13:560-572.
65. Falhiel-Morel A, Chafai M, Vaudry D, Basille M, Cazillis M, Aubert N, Louiset E, de Jouffrey S, Le Bigot JF, Fournier A, Gressens P, Rostene W, Vaudry H, Gonzalez BJ. 2007. The neuropeptide pituitary adenylate cyclase-activating polypeptide exerts anti-apoptotic and differentiating effects during neurogenesis: focus on cerebellar granule neurones and embryonic stem cells. J Neuroendocrinol 19:321-327.
66. Fang F, Morean J L, Fields H L. 1987. Dose dependent antinociceptive action of neurotensin microinjected into the rostroventromedial medulla of the rat. Brain Res 420:171-174.
67. Firth SI, Kaufman PL, De Jean BJ, Byers JM, Marshak DW. 2002. Innervation of the uvea by galanin and somatostatin immunoreactive axons in macaques and baboons. Exp Eye Res 75:49-60
68. Fischer MJ, Koulchitsky S, Messlinger K. 2005. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 25:5877-5883.
69. Freitag FG, Diamond S, Diamond ML, Urban GJ. 2001. Divalproex in the long-term treatment of chronic daily headache. Headache 41:271-278.
70. Freitag FG, Lake A III, Lipton R, Cady R, Diamond S, Silberstein S. US Headache Guidelines Consortium, Section on Inpatient Treatment Chairpersons. 2004. Inpatient treatment of headache: an evidence-based assessment. Headache 44:342-360.
71. Freitag FG. 2007. The cycle of migraine: patients' quality of life during and between migraine attacks. Clin Ther 29:939-949.
72. Friberg L, Olesen J, Olsen TS, Karle A, Ekman R, Fahrenkrug J. 1994. Absence of vasoactive peptide release from brain to cerebral circulation during onset of migraine with aura. Cephalalgia 14:47-54.
73. Fusayasu E, Kowa H, Takeshima T, Nakaso K, Nakashima K. 2007. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 128:209-214.
74. Gallai V, Sarchielli P, Flofidi A, Francceschini M, Godini M, Trequattrini A, Palumbo R. 1995. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia, 15:384-390.
75. Gamse R, Saria A. 1985. Potentiation of tachykinin-induced plasma protein extravasation by calcitonin gene-related peptide. Eur J Pharmacol 114:61-66.
76. Gamse R, Saria A. 1986. Nociceptive behavior after intrathecal injection of substance P, neurokinin A and calcitonin gene-related peptide in mice. Neurosci Lett 70:143-147.
77. Gazelius B, Brodin E, Olgart L, Panopoulos P. 1981. Evidence that substance P is a mediator of antidromic vasodilatation using somatostatin as a release inhibitor. Acta Physiol Scand 113:155-159.
78. Géraud G, Denuelle M, Fahre N, Payoux P, Chollet F. 2005. Positron emission tomographic studies of migraine. Rev Neurol (Paris) 161:666-670.
79. Gioia M, Bianehi R. 1991. Ultrastructure of substance P immunoreactive elements in the periaqueductal gray mater of the rat. Peptides 12:1235-1238.
80. Goadsby PJ. 1997a. Is a central action of acute antimigraine drugs essential? Cephalalgia 17:10-11.
81. Goadsby PJ. 1997b. Current concepts of the pathophysiology of migraine. Neurol Clin 15:27-42.
82. Goadsby PJ. 2007. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 13:39-44.
83. Goadsby PJ, Edvinsson L. 1993. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48-56.
84. Goadsby PJ, Edvinsson L. 1996. Neuropeptide changes in case of chronic paroxysmal hemicrania- evidence for trigemino-parasympathetic activation. Cephalalgia 16:448-450.
85. Goadsby PJ, Knight Y. 1997. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT1B/1D) receptors. Br J Pharmacol 122:918-922.
86. Goadsby PJ, Boes CJ. 2001. Zolmitriptan: differences from sumatriptan. Curr Med Res Opin 17:S46-50.
87. Goadsby PJ, Edvinsson L, Ekman R. 1988. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23:193-196.
88. Goadsby PJ, Edvinsson L, Ekman R. 1990. Vasoactive peptide release in the extracerebral circulation of human during migraine headache. Ann Neurol 28:183-187.
89. Goadsby PJ, Adner M, Edvinsson L. 1996. Characterization of endothelin receptors in the cerebral vasculature and their lack of effect on spreading depression. J Cereb Blood Flow Metab 16:698-704.
90. Goadsby PJ, Lipton RB, Ferrari MD. 2002. Migraine, current understanding and treatment. N Engl J Med 346:257-270.
91. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT. 1997. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17:785-790.
92. González-Rey E, Varela N, Chorny A, Delgado M. 2007. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr Pharm Des 13:1113-1139.
93. Goodman EC, Iversen LL. 1986. Calcitonin gene-related peptide: novel neuropeptide. Life Sci 38:2169-2178.
94. Greves LE, Nyberg F, Terenius L, Hökfelt T. 1985. Calcitonin gene-related peptide is a potent inhibitor of substance P degradation. Eur J Pharmacol 115:309-311.
95. Gupta S, Mehrotra S, Villalón CM, Garrelds IM, de Vries R, van Kats JP, Sharma HS, Saxena PR, Maassen van den brink A. 2006a. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur J Pharmacol 530:107-116.
96. Gupta S, Akerman S, van den Maagdenberg AM, Saxena PR, Goadsby PJ, van den Brink AM. 2006b. Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine. Cephalalgia 26:1294-1303.
97. Gupta S, Mehrotra S, Villalón C, De Vries R, Garrelds I, Saxena P, Vandenbrink AM. 2007a. Effects of female sex hormones on responses to CGRP, acetylcholine, and 5-HT in rat isolated arteries. Headache 47:564-575.
98. Gupta S, Mehrotra S, Villalón CM, Perusquia M, Saxena PR, MaassenVanDenBrink A. 2007b. Potential role of female sex hormones in the pathophysiology of migraine. Pharmacol Ther 113:321-340.
99. Hamel E. 1999. The biology of serotonin receptors: focus on migraine pathophysiology and treatment. Can J Neurol Sci 26(Suppl 3):S2-S6.
100. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J, Olesen J, Ashina M. 2006. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 26:992-1003.
101. Hansson E, Muyderman H, Leonova J, Allansson L, Sinclair J, Blomstrand F, Thorlin T, Nilsson M, Ronnback L. 2000. Astroglia and glutamate in physiology and pathology: aspects on glutamate transport, glutamate-induced cell swelling and gap-junction communication. Neurochem Int 37:317-329.
102. Hargreaves R. 2007. New migraine and pain research. Headache 47(Suppl 1):S26-S43.
103. Hasbak P, Saetrum Opgaard O, Eskesen K, Schiffer S, Arendrup H, Longmore J, Edvinsson L. 2003. Investigation of GGRP receptors and peptide pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J Pharmacol Exp Ther 304:326-333.
104. Hautmann M, Friis UG, Desch M, Todorov V, Castrop H, Segerer F, Otto C, Schutz G, Schweda F. 2007. Pituitary adenylate cyclase-activating polypeptide stimulates renin secretion via activation of PAC1 receptors. J Am Soc Nephrol 18:1150-1156.
105. Hay DL, Howitt SG, Conner AC, Doods H, Schindler M, Poyner DR. 2002. A comparison of the actions of BIBN4096BS and CGRP8-37 on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells. Br J Pharmacol 137:80-86.
106. Herman ZS, Stachura Z. 1993. Pharmacological interaction between neuropeptides and pethidine or fentanyl in rat spinal cord. Pol J Pharmacol 45:481-492.
107. Holland PR, Akerman S, Goadsby PJ. 2006. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 24:2825-2833.
108. Hoskin KL, Kaube H, Goadsby PJ. 1996. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 119:1419-1428.
109. Houghton LA, Fowler P, Keene ON, Read NW 1992. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 6:685-691.
110. Howland RD, Mycek MJ. 2006. In: Harvey RA, Champe PC, editors. Pharmacology. Philadelphia: Lippincott Williams & Wilkins. p 520-523.
111. Hozler P. 1988. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 24:739-768.
112. Humphrey PP. 2007. The discovery of a new drug class for the acute treatment of migraine. Headache 47(Suppl 1):S10-S19.
113. Hylden J L, Wilcox G L. 1981. Intrathecal substance P elicits a caudally-directed biting and scratching behaviour in mice. Brain Res 217:212-215.
114. Hylden JLK, Wilcox GL. 1983. Antinociceptive action of intrathecal neurotensin in mice. Peptides 4:517-520.
115. Iversen HK. 2001. Human migraine models. Cephalalgia 21:781-785.
116. Jansen-Olesen I, Kaarill L, Edvinsson L. 2001. Characterization of CGRP1 receptors in the guinea pig basilar artery. Eur J Pharmacol 414:249-258.
117. Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L. 2003. In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 481:207-216.
118. Just S, Arndt K, Doods H. 2005. The role of CGRP and nicotinic receptors in centrally evoked facial blood flow changes. Neurosci Lett 381:120-124.
119. Kafitz KW, Rose CR, Thoenen H, Konnerth A. 1999. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature 401:918-921.
120. Kai-Kai MA. 1989. Cytochemistry of the trigeminal and dorsal root ganglia and spinal cord of the rat. Comp Biochem Physiol A 93:183-193.
121. Kalivas PW, Jennes L, Nemeroff CB, Prange AJ. 1982. Neurotensin: topographical distribution of brain sites involved in hypothermia and antinociception. J Comp Neurol 210:225-238.
122. Kapieioglu S, Gokce E, Kapicioglu Z, Ovali E. 1997. Treatment of migraine attacks with a long-acting somatostatin analogue (Octreotide. SMS 201-995). Cephalalgia 17:27-30.
123. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. 1993. Expression of c-fos like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in cat. Brain Res 629:95-102.
124. Keller JT, Marfurt CF. 1991. Peptidergic and serotoninergic innervation of the rat dura mater. J Comp Neurol 309:515-534.
125. Kemper RH, Jeuring M, Meijler WJ, Korf J, Ter Horst GJ. 2000. Intracisternal octreotide does not ameliorate orthodromic trigeminovascular nociception. Cephalalgia 20:114-121.
126. Kitazawa T, Terasaki T, Suzuki H, Kakee A, Sugiyama Y. 1998. Efflux of taurocholic acid across the blood-brain barrier: interaction with cyclic peptides. J Pharmacol Exp Ther 286:890-895.
127. Klapper J. 1997. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17:103-108.
128. Knight Y, Bartsch T, Kaube H, Goadsby P. 2002. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 22:RC213.
129. Knyihar-Csillik E, Tajti J, Samsam M, Véesei L. 1994. Central representation of CGRP-positive trigeminal neurons in the medulla oblongata of the albino rat. European Headache Federation, The 2nd international conference on Headache, Liege, Belgium, Abstract p 41.
130. Knyihar-Csillik E, Tajti J, Samsam M, Sáry G, Vécsei L. 1995. Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache. Neurosci Lett 184:189-192.
131. Knyihár-Csillik E, Samsam M, Tajti J, Sáry Gy, Buzas P, Vécsei L. 1996. Anatomical basis of headache: changes in the intracellular equilibrium of a pain-related neuropeptide in an experimental migraine model. Ann Anat 178:220.
132. Knyihár Csillik E, Tajti J, Samsam M, Sáry G, Buzás P, Véesei L. 1997. Effect of a serotonin agonist (Sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J Neurosci Res 48:449-464.
133. Knyihár Csillik E, Tajti J, Samsam M, Sáry G, Buzás P, Vécsei L. 1998. Depletion of calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat after electrical stimulation of the Gasserian ganglion. Exp Brain Res 118:111-114.
134. Kors EE, Vaumolkot KR, Haan J, Frants RR, van den Maagdenberg AM, Ferrari MD. 2004. Recent findings in headache genetics. Curr Opin Neurol 17:283-288.
135. Kruuse C, Thomsen L, Birk S, Oleesen J. 2003. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126:241-247.
136. Lambert GA, Boers PM, Hoskin KL, Donaldson C, Zagami AS. 2002. Suppression by eletriptan of the activation of trigemino-vascular sensory neurons bv glyceryl trinitrate. Brain Res 953:181-188.
137. Langemark M, Bach F W, Ekman R, Olesen J. 1995. Increased cerebrospinal fluid Met-enkephalin immunoreactivity in patients with chronic tension-type headache. Pain 63:103-107.
138. Lassen LH, Haderslev PA, Jaeobsen VB, Iversen HK, Sperling B, Olesen J. 2002. CGRP may play a causative role in migraine. Cephalalgia 22:54-61.
139. Lauritzen M. 2001. Cortical spreading depression in migraine. Cephalalgia 21:757-760.
140. Lauritzen M, Olsen T, Lassen N, Paulson O. 1983. Regulation of regional cerebral blood flow during and between migraine attacks. Ann Neurol 14:569-572.
141. Lazarov NE. 2002. Comparative analysis of the chemical neuroanatomy of the mammalian trigeminal ganglion and mesencephalic trigeminal nucleus. Prog Neurobiol 66:19-59.
142. Leibowitz DH. 1992. The glial spike theory. I. On an active role of neuroglia in spreading depression and migraine. Proc Biol Sci 250:287-295.
143. Lembeck F 1983. Peripheral substance P neurons, afferent, efferent or both functions? In: Skrabanek P, Powell D, editors. Substance P. Dublin: Boole Press. p 81-85.
144. Lembeck F, Gamse R. 1977. Lack of algesia effect of substance P on paravascular pain receptors. Naunyn Schmiedebergs Arch Pharmacol 29:295-303.
145. Levy D, Jakubowski M, Burstein R. 2004. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci USA 101:4274-4279.
146. Linde M. 2006. Migraine: a review and future directions for treatment. Acta Neurol Scand 114:71-83.
147. Lisi V, Garbo G, Battistella P, Miccichè F, Steeca A, Terrazzino S, Franzoi M, Tripoli E, Leon A, Clementi M. 2006. Endothelin receptor A-231 A/G polymorphism: no linkage to primary pediatric headache. Headache 46:486-491.
148. Longmore J, Razzaque Z, Shaw D, Davenport AP, Maguire J, Pickard JD, Schofield WN, Hill RG. 1998. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br J Clin Pharmacol 46:577-582.
149. Maassen VanDenBrink A, van den Broek RW, de Vries R, Bogers AJ, Avezaat CJ, Saxena PR. 2000. Craniovaseular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55:1524-1530.
150. Maassen Van Den Brink A, Saxena PR. 2004. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Headache 44(Suppl 1):S13-S19.
151. Markhotina N, Liu GJ, Martin DK. 2007. Contractility of retinal pericytes grown on silicone elastomer substrates is through a protein kinase A-mediated intracellular pathway in response to vasoactive peptides. IET Nanobiotechnol 1:44-51.
152. Markowitz S, Saito K, Moskowitz M. A. 1987. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129-4136.
153. Martin-Schild S, Gerall A A, Kastin A J, Zadina J E. 1998. Endomorphin-2 is an endogenous opioid in primary sensory afferent fibers. Peptides 19:1783-1789.
154. Masmoudi-Kouki O, Gandolfo P, Castel H, Leprince J, Fournier A, Dejda A, Vaudry H, Tonon MG. 2007. Role of PACAP and VIP in astroglial functions. Peptides (in press).
155. Massari VJ, Tizabi Y, Park CH, Moody TW, Halke CJ, ÓDonohue TL. 1983. Distribution and origin of bombesin, substance P and somatostatin in cat spinal cord. Peptides 4:673-681.
156. Matharu MS, Bartsch T, Ward N, Frackwiak RS, Weiner R, Goadsby PJ. 2004. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127:220-230.
157. Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber GJ, Deaton RL. 1995. Migraine prophylaxis with divalproex. Arch Neurol 52:281-286.
158. Mathew NT, Kailasam J, Meadors L. 2002. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache 42:796-803.
159. Matsubara T, Moskowitz MA, Huang Z. 1992. UK-14,304, R(-)-alpha-methyl- histamine and SMS201-995 block plasma protein leakage within dura mater by prejunctional mechanism. Eur J Pharmacol 224:145-150.
160. May A, Gijsman HJ, Wallnoefer A, Jones R, Diener HC, Ferrari MD. 1996. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67:375-378.
161. May A, Buchel C, Turner R, Goadsby PJ. 2001. Magnetic resonance angiography in facial and other pain: neurovascular mechanisms of trigeminal sensation. J Cereb Blood Flow Metab 21:1171-1176.
162. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. 1998. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333-339.
163. Messlinger K, Hanesch U, Kurosawa M, Pawlak M, Schmidt RF. 1995. Calcitonin gene-related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can J Physiol Pharmacol 73:1020-1024.
164. Messlinger K, Suzuki A, Pawlak M, Zehnter A, Schmidt RF. 2000. Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat. Br J Pharmacol 129:1397-1404.
165. Miller KE, Salvatierra AT. 1998. Apposition of enkephalin- and neurotensin-immunoreactive neurons by serotonin-immunoreactive varicosities in the rat spinal cord. Neuroscience 85:837-846.
166. Mitsikostas DD, Sánchez del Río M, Waeber C, Moskowitz MA, Gutrer FM. 1998. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 76:239-248.
167. Monteiro JM., Rosas MJ, Correia AP, Vaz AR. 1993. Migraine and intracranial vascular malformations. Headdache 33:563-565.
168. Moskowitz MA. 1984. The neurobiology of vascular head pain. Ann Neurol 16:157-168.
169. Moskowitz M A, Brezina L R, Kuo C. 1986. Dynorphin B-containing perivascular axons and sensory neurotransmitter mechanisms in brain blood vessels. Cephalalgia 6:81-86.
170. Mosnaim AD, Wolf ME, Chevesich J, Callaghan OH, Diamond S. 1985. Plasma methionine enkephalin levels. A biological marker for migraine? Headache 25:259-261.
171. Mosnaim AD, Chevesich J, Wolf ME, Freitag FG, Diamond S. 1986. Plasma methionine enkephalin. Increased levels during a migraine episode. Headache 26:278-281.
172. Nakamura H, Yoshino S. 1990. Opioid peptides in RA: modulation of immunologic mechanisms and mental states. Arerugi 39:110-117.
173. Negri M, Lomanto D, Tonnarini G, Bernardinis G B, d'Alessandro M, Mariani P, Speranza V. 1993. Plasma opioid levels during extracorporeal gallstone lithotripsy. Am J Gastroentrol 88:1093-1096.
174. Nichols FI, Mawad M, Mohr J, Stein B, Hilal S, Michelsen J. 1990. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke 21:555-559.
175. Nikolodi M, Del Bianco E. 1990. Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polypeptide in human saliva: their pattern in migraine and cluster headache. Cephalalgia 10:39-50.
176. Noll G, Wenzel RR, Lüscher TF. 1996. Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease. Mol Cell Biochem 157:259-267.
177. Nozaki K, Boccalin P, Moskowitz M A. 1992. Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience 49:669-680.
178. O'Connor TP, Van der Kooy D. 1988. Enrichment of a vasoactive neuropeptide (calcitonin gene-related peptide) in the trigeminal sensory
179. Oku R, Satoh M, Fujii N, Otaka A, Yajima H, Takagi H. 1987. Caclitonin gene-related paptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res 403:350-354.
180. Olesen J, Friberg L, Olesen T, Iversen HK, Lassen NA, Andersen AR, Karle A. 1990. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 28:791-798.
181. Olesen J, Bonica JJ. 1990. Headache. In: Bonica JJ, editor. Management of Pain. Philadelphia: Lea & Febigera. Volume I. p 687-726.
182. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM; BIBN, 4096 BS Clinical Proof of Concept Study Group. 2004. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104-1110.
183. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SM, Lamerdin JE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR. 1996. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543-552.
184. Ophoff RA, Van den Maagdenberg AM, Roon KI, Ferrari MD, Frants RR. 2001. The impact of pharmacogenetics for migraine. Eur J Pharmacol 413:1-10.
185. Ositelu DO, Morris R, Vaillant C. 1987. Innervation of facial skin but not masticatory muscles or the tongue by trigeminal primary afferents containing somatostatin in the rat. Neurosci Lett 78:271-276.
186. Otsuka M, Konishi S. 1976. Release of substance P-like immunoreactivity from isolated spinal cord of new born rat. Nature 264:83-84.
187. Pardutz A, Hoyk Z, Varga H, Vecsei L, Schoenen J. 2007. Oestrogen-modulated increase of cahnodulin-dependent protein kinase II (CamKII) in rat spinal trigeminal nucleus after systemic nitroglycerin. Cephalalgia 27:46-53.
188. Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L, Jansen I, Olesen J. 1991. Calcitonin gene-related peptide, neurokinin A and substance P: effects on nociception and neurogenic inflammation in human skin and temporal muscle. Peptides 12:333-337.
189. Penfield W, McNaughton F. 1983. Dural headaches and the innervation of the dura mater. Am Neurol Assoc 64:106-109.
190. Peroutka SJ. 2005. Neurogenic inflammation and migraine: implications for the therapeutics. Mol Interv 5:304-311.
191. Piercey M F, Dobry P J, Schroeder L A, Einspahr F J. 1981. Behavioural evidence that substance P may be a spinal cord sensory neurotransmitter. Brain Res 210:407-412.
192. Polley JS, Gaskin PJ, Perren MJ, Connor HE, Ward P, Beattie DT. 1997. The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system. Regul Pept 68:23-29.
193. Rahimtoola H, Buurma H, Tijssen GC, Leufkens HG, Egberts AC. 2003. Migraine prophylactic medication usage patterns in The Netherlands. Cephalalgia 23:293-301.
194. Ramadan NM. 2003. The link between glutamate and migraine. CNS Spectr 8:446-449.
195. Reichlin S. 1983. Somatostatin. N Engl J Med 309:1495-1501.
196. Reichling D, Basbaum A. 1990. Contribution of brainstem GABAergic circuitry to descending antinociceptive controls I. GABA-immunoreactive projection neurons in the periaque-ductal gray and nucleus raphe megnns. J Comp Neurol 302:370-377.
197. Reichling DB, Kwait GC, Basbaum A I. 1988. Anatomy and pharmachology of the periaqueductal gray contribution to antinociceptive controls. Prog Brain Res 77:31-46.
198. Ruiz-Gayo M, González MC, Fernández-Alfonso S. 2006. Vasodilatory effects of eholecystokinin: new role for an old peptide? Regul Pept 137:179-184.
199. Samsam M, Knyihár-Csillik E, Sáry G, Vécsei L. 1996. Effects of lesions of the Gasserian ganglion on the CGRP immunoreactivity of the caudal trigeminal nucleus. Neurobiology 4:169.
200. Samsam M, Coveñas R, Ahangari R, Yajeya J, Narvaéz JA, Tramu G. 1999. Alterations in neurokinin A, substance P and calcitonin gene-related peptide immunoreactivities in the caudal trigeminal nucleus of the rat following electrical stimulation of the trigeminal ganglion. Neurosci Let 261:179-182.
201. Samsam M, Coveñas R, Ahangari R, Yajeva J, Narvaéz JA, Tramu G. 2000. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain 84:389-395.
202. Samsam M, Coveñas R, Csillik B, Ahangari R, Yajeva J, Riqnelme R, Narvaéz JA, Tramu G. 2001. Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion: a possible, neurophysiological and neuroanatomical link to generalized head pain. J Chem Neuroanat 21:161-169.
203. Samsam M, Coveñas R, Ahangari M, Yajeva J, Narváez JA, Montes C, González-Barón S. 2002. Implication of the neuropeptides methionine enkephalin, neurotensin and somatostatin of the caudal trigeminal nucleus in the experimental migraine. Rev Neurol 34:724-729.
204. Sandor P, Afra J, Proietti Cecchini A, Albert A, Schoenen J. 2005. From neurophysiology to genetics: cortical information processing in migraine underlies familial influences - a novel approach. Funct Neurol 3:68-72.
205. Sanya E, Brown C, Von Wihnowsky C, Neundorfer B, Hilz M. 2005. Impairment of parasympathetic baroreflex responses in migraine patients. Acta Neurol Scand 111:102-107.
206. Saria A, Ma RC, Dun NJ. 1985. Neurokinin A depolarizes neurons of the guinea pig inferior mesentric ganglia. Neurosci Lett 60:145-150.
207. Saria A, Hauser K F, Traurig H H, Turbek C S, Hersh L, Gerard C. 1997. Opioid-related changes in nociceptive threshold and in tissue levels of enkephalins after target disruption of the gene for neutral endopeptidase (EC 3.4.24.11) in mice. Neurosci Lett 234:27-30.
208. Saxena PR. 1994. Progress in 5-HT receptor classification. Newsl Eur Headache Fed (EHF) 3:1-8.
209. Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, Schicha H. 1998. Somatostatin receptor imaging in intracranial tumors. Fur J Nucl Med 25:675-686.
210. Schulman E, Dermott K. 2003. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 43:729-733.
211. Seybold V S, Hylden J L, Wilcox G L. 1982. Intrathecal substance P and somatostatin in rats: behaviours indicative of sensation. Peptides 3:49-54.
212. Sharp B, Yaksh T. 1997. Pain killers of the immune system. Nat Med 3:831-832.
213. Shepheard SL, Williamson DJ, Hill RG, Hargreaves RJ. 1993. The non-peptide neurokinin1 receptor antagonist RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br J Pharmacol 108:11-12.
214. Shiga H, Yoshino S, Nakamura H, Koiwa M. 1993. Role of opioid peptide in rheumatoid arthritis: detection of methionine-enkephalin and leucine-enkephalin in synovial tissue. Arerugi 42:243-249.
215. Sicuteri F, Geppetti P, Marabini S, Lembeck F. 1984. Pain relief by somatostatin in attacks of cluster headache. Pain 18:359-365.
216. Sicuteri F, Renzi D, Geppetti P. 1986. Substance P and enkephalins: a creditable tandem in the pathophysiology of cluster headache and migraine. Adv Exp Med Biol 198:145-152.
217. Silberstein SD, Collins SD. 1999. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache 39:633-643.
218. Silberstein SD. 2004. Migraine pathophysiology and its clinical implications. Cephalalgia 24(Suppl 2):2-7.
219. Silberstein SD. 2005. Topiramate in migraine prevention. Headache 45(Suppl 1):S57-65.
220. Silvestrini M, Cupini LM, Calabresi P, Floris R, Bernardi G. 1992. Migraine with aura-like syndrome due to arteriovenous malformation. The clinical value of transcranial Doppler in early diagnosis. Cephalalgia 12:11.5-119.
221. Skofitsch G, Zamir N, Helke CJ, Savitt JM, Jacobowitz DM. 1985. Corticotropin releasing factor-like immunoreactivity in sensory ganglia and capsaicin sensitive neurons of the rat central nervous system: co-localization with other neuropeptides. Peptides 6:307-318.
222. Smith DJ, Hawranko AA, Monroe PJ, Gully D, Urban MO, Craig CR, Smith JP, Smith DL. 1997. Dose dependent pain facilitatory and inhibitory actions of neurotensin are revealed by SR48692, a nonpeptide neurotensin antagonist: influence on the antinociceptive effect of morphine. Pharmacol Exp Ther 282:899-908.
223. Spampinato S, Romualdi P, Candelotti S, Cavicchini E, Ferri S. 1988. Distinguishable effects of intrathecal dynorphins, somatostatin, neurotensin and S-calcitonin on nociception and motor function in the rat. Pain 35:95-194.
224. Spierings ELH. 2003. Pathogenesis of the migraine attack. Clin J Pain 19:255-262.
225. Spierings ELH. 2004. The aura-headache connection in migraine: a historical analysis. Arch Neurol 61:794-799.
226. Stein C, Hassan A H S, Przewlocki R, Gramsch G, Peter K, Herz A. 1990a. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci USA 87:593.5-5939.
227. Stein C, Gramsch C, Herz A. 1990b. Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. J Neurosci 10:1292-1298.
228. Storer RJ, Akerman S, Goadsby PJ. 2004. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171-1181.
229. Strecker T, Dux M, Messlinger K. 2002. Increase in meningeal blood flow by nitric oxide - interaction with calcitonin gene-related peptide receptor and prostaglandin synthesis inhibition. Cephalalgia 22:233-241.
230. Suzuki N, Yoshino S, Nakamura H. 1992. A study of opioid peptides in synovial fluid and synovial tissue in patients with rheumatoid arthritis. Arerugi 41:615-620.
231. Theoharides TG, Donelan J, Kandere-Grzybowska K, Konstantinidou A. 2005. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev 49:65-76.
232. Thomsen LL, Olesen J. 2001. Nitric oxide in primary headaches. Curr Opin Neurol 14:315-321.
233. Troltzsch M, Denekas T, Messlinger K. 2007. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. Eur J Pharmacol 562:103-110.
234. Troost BT, Mark LE, Maroon JC. 1979. Resolution of classic migraine after removal of an occipital lobe AVM. Ann Neurol 5:199-201.
235. Tsimikas S. 2005. Transcatheter closure of patent foramen ovale for migraine prophylaxis: hope or hype? J Am Coll Cardiol 45:496-498.
236. Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alpérovitch A. 2001. Association between migraine and endothelin type A receptor (ETA -231 A/G) gene polymorphism. Neurology 56:1273-1277.
237. Uddman R, Edvinsson L. 1989. Neuropeptides in the cerebral circulation. Cerebrovas Brain Metab Rev 1:230-252.
238. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. 1985. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 62:131-136.
239. Uddman R, Edvinsson L, Jansen I, Stiernholm P, Jensen K, Olesen J, Sundler F. 1986. Peptide-containing nerve fibers in human extracranial tissue: A morphological basis for neuropeptide involvement in extracranial pain? Pain 27:391-399.
240. Van den Broek RW, MaassenVanDenBrink A, de Vries R, Bogers AJ, Stegmann AP, Avezaat CJ, Saxena PR. 2000. Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. Eur J Pharmacol 407:165-173.
241. Vanmolkot KR, Kors EE, Hottenga JJ, Terwindt GM, Haan J, Hoefnagels WA, Black DF, Sandkuijl LA, Frants RR, Ferrari MD, van den Maagdenberg AM. 2003. Novel mutations in the Na+, K + -ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol 54:360-366.
242. Varga H, Párdutz A, Tajti J, Vécsei L, Schoenen J. 2006. The modulatory effect of estrogen on the caudal trigeminal nucleus of the rat in an animal model of migraine. Ideggyogy Sz. 59:389-395.
243. Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. 2002. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc 45:199-210.
244. Villalón CM, Centurión D, Valdivia LF, de Vries P, Saxena PR. 2003. Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol 1:71-84.
245. Vincent MB, Ekman R, Edvinsson L, Sand T, Sjaastad O. 1992. Reduction of calcitonin gene-related peptide in jugular blood following electrical stimulation of rat greater occipital nerve. Cephalalgia 12:275-279.
246. Wasay M, Zaki KS, Khan SU, Rehmani R. 2006. Narcotic analgesics for acute migraine in the emergency room: are we meeting Headache Societies' guidelines? J Headache Pain 7:413-415.
247. Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC. 1995. Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658-660.
248. Welch KM, Nagesh V, Aurora SK, Gelman N. 2001. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 41:629-637.
249. Wessman M, Kaunisto MA, Kallela M, Palotie A. 2004. The molecular genetics of migraine. Ann Med 36:462-473.
250. Wiesenfeld-Halin Z, Hökfelt T, Lundberg JM, Forssmann WG, Reinecke M, Tschopp FA, Fischer JA. 1984. Immunoreactive calcitonin gene-related peptide and substance P co-exist in sensory neurons to the spinal cord and interact in spinal behavioural responses of the rat. Neurosci Lett 52:199-204.
251. Williamson DJ, Shepheard SL, Cook DA, Hargreaves RJ, Hill RG, Cumberbatch MJ. 2001a. Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats. Br J Pharmacol 133:807-814.
252. Williamson DJ, Hill RG, Shepheard SL, Hargreaves RJ. 2001b. The anti-migraine 5-HT1B/1D agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol 133:1029-1034.
253. Wilmshurst P, Nightingale S. 2001. Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin Sci (Lond) 100:215-220.
254. Wolff HG. 1943. Pain, research publication association of research and nervous and mental diseases, Vol. 23. Baltimore; Williams & Wilkins.
255. Woolf C, Wiesenfeld-Hallin Z. 1986. Substance P and calcitonin gene-related peptide synergistically modulate the gain of the nociceptive flexor withdrawal reflex in the rat. Neurosci Let 66:226-230.
256. Wu D, Eberlein W, Rudolf K, Engel W, Hallermayer G, Doods H. 2000. Characterisation of calcitonin gene-related peptide receptors in rat atrium and vas deferens: evidence for a [Cys(Et)(2, 7)]hCGRP-preferring receptor. Eur J Pharmacol 400:313-319.
257. Wu D, Doods H, Arndt K, Schindler M. 2002. Development and potential of non-peptide antagonists for calcitonin-gene-related peptide (CGRP) receptors: evidence for CGRP receptor heterogeneity. Biochem Soc Trans 30:468-473.
258. Yaksh TL, Elde R. 1981. Factors governing release of methionine- enkephalin-like immunoreactivitv from mesencephalon and spinal cord of the cat in vivo. J. Neurophysiol 46:1056-1075.
259. Yaksh T, Young C, Rudy T. 1976. Systematic examination of the rat brain sites sensitive to direct application of morphin: Observation of differential effects with the periaqueductal gray. Brain Res 114:83-103.
260. Yaksh T L, Jessell T M, Gamse R, Mudge A W, Leeman S E. 1980. Intrathecal morphin inhibits substance P release from mammalian spinal cord in vivo. Nature 286:155-157.
261. Yaksh TL, Schmauss C, Micevych PE, Abay EO, Go VLV. 1982. Pharmacological studies on the application, disposition and release of neurotensin in the spinal cord. Ann NY Acad Sci 400:228-243.
262. Yaksh T L, Michener S R, Bailey J E, Harty G J, Lucas D L, Nelson D K, Roddy D R, Go V L. 1988. Survey of distribution of substance P, vasoactive intestinal peptide, cholecystokinin, neurotensin, Met-enkephalin, bombesin and PHI in the spinal cord of the cat, dog, sloth and monkey. Peptides 9:357-372.
263. Young WB, Hopkins MM, Shechter AL, Silberstein SD. 2002. Topiramate: a case series study in migraine prophylaxis. Cephalalgia 22:659-663.
264. Zagon IS, McLaughlin PJ. 2006. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Int J Oncol 29:489-494.
265. Zhang RX, Mi Z P, Qiao JT. 1994. Changes of spinal substance P, calcitonin gene-related peptide, somatostatin, Met-enkephalin and neurotensin in rats in response to formalin-induced pain. Regul Pept 51:25-32.
266. Zhang X, Strassman AM, Burstein R, Levy D. 2007. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther 322:806-812.
267. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF 2007. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 27:2693-2703.
268. Zhao C, Tao Z, Xiao S, Zhao S, Qiao J. 1998. Histochemical and immunohistochemical studies of distribution of acetylcholinesterase-positive fibers and peptidergic terminals in the nasal mucosa of rats. Chin Med J (Engl) 111:644-647.
269. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. 1987. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 44:486-489.
270. Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. 1993. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 50:825-830.